Format

Send to

Choose Destination
J Am Coll Cardiol. 2017 Jun 6;69(22):2759-2768. doi: 10.1016/j.jacc.2017.04.010.

LOX-1 in Atherosclerosis and Myocardial Ischemia: Biology, Genetics, and Modulation.

Author information

1
Division of Cardiovascular Medicine, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas; Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
2
Cardiovascular and Metabolic Diseases, Innovative Medicines Biotech Unit, Medimmune Inc., Gaithersburg, Maryland.
3
International Centre for Genetic Engineering and Biotechnology, New Delhi, India; Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
4
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
5
Division of Cardiovascular Medicine, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas; Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas; Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas. Electronic address: mehtajl@uams.edu.

Abstract

Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), one of the scavenger receptors for oxidized low-density lipoprotein cholesterol (ox-LDL), plays a crucial role in the uptake of ox-LDL by cells in the arterial wall. Mounting evidence suggests a role for LOX-1 in various steps of the atherosclerotic process, from initiation to plaque destabilization. Studies of the genetic structure of LOX-1 have also uncovered various genetic polymorphisms that could modulate the risk of atherosclerotic cardiovascular events. As evidence supporting the vital role of LOX-1 in atherogenesis keeps accumulating, there is growing interest in LOX-1 as a potential therapeutic target. This review discusses the discovery and genetics of LOX-1; describes existing evidence supporting the role of LOX-1 in atherogenesis and its major complication, myocardial ischemia; and summarizes LOX-1 modulation by some naturally occurring compounds and efforts toward development of small molecules and biologics that could be of therapeutic use.

KEYWORDS:

LOX-1 blockers; coronary artery disease; endothelial cells; low-density lipoprotein; myocardial infarction; reactive oxygen species

PMID:
28571642
DOI:
10.1016/j.jacc.2017.04.010
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center